MGMT and central nervous system cancer: The relevance of MGMT methylation as a biomarker has been strengthened by the widely accepted application of the consensus reached in Phase III clinical trials jointly conducted by European and North-American research networks, that were summarized in the so-termed ‘Stupp protocol’ for the first line treatment of patients affected by gliomas, which includes the post-surgery association of radiotherapy and temozolomide (47).